 Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and impacts approximately six per 100,000 individuals in North America and Europe. Current treatments are inadequate because they only address a small segment of the Duchenne muscular dystrophy population, leaving a huge unmet need. 